Virtu Financial LLC Invests $152,000 in Anavex Life Sciences Corp (NASDAQ:AVXL) Stock

Virtu Financial LLC purchased a new position in shares of Anavex Life Sciences Corp (NASDAQ:AVXL) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 49,580 shares of the biotechnology company’s stock, valued at approximately $152,000. Virtu Financial LLC owned 0.10% of Anavex Life Sciences as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the company. Deutsche Bank AG bought a new position in Anavex Life Sciences in the 4th quarter worth about $28,000. Edge Wealth Management LLC raised its holdings in shares of Anavex Life Sciences by 200.0% in the 1st quarter. Edge Wealth Management LLC now owns 30,000 shares of the biotechnology company’s stock valued at $91,000 after acquiring an additional 20,000 shares in the last quarter. Hikari Power Ltd purchased a new stake in shares of Anavex Life Sciences in the 4th quarter valued at about $231,000. Tibra Equities Europe Ltd purchased a new stake in shares of Anavex Life Sciences in the 1st quarter valued at about $258,000. Finally, Geode Capital Management LLC raised its holdings in shares of Anavex Life Sciences by 1.3% in the 4th quarter. Geode Capital Management LLC now owns 291,948 shares of the biotechnology company’s stock valued at $455,000 after acquiring an additional 3,687 shares in the last quarter. Institutional investors own 14.58% of the company’s stock.

Several analysts have weighed in on the company. ValuEngine raised Anavex Life Sciences from a “hold” rating to a “buy” rating in a report on Wednesday, May 15th. Zacks Investment Research raised Anavex Life Sciences from a “sell” rating to a “hold” rating in a report on Wednesday, April 10th. Finally, Roth Capital set a $10.00 price target on Anavex Life Sciences and gave the stock a “buy” rating in a research note on Friday, February 8th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $7.50.

Anavex Life Sciences stock traded down $0.10 during trading hours on Wednesday, reaching $3.60. The company had a trading volume of 467,674 shares, compared to its average volume of 330,567. The stock has a market capitalization of $176.57 million, a P/E ratio of -9.22 and a beta of 2.47. Anavex Life Sciences Corp has a 12-month low of $1.25 and a 12-month high of $4.35.

Anavex Life Sciences (NASDAQ:AVXL) last announced its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.13) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.01. As a group, sell-side analysts forecast that Anavex Life Sciences Corp will post -0.67 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Sundance Herald and is the property of of Sundance Herald. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at https://sundanceherald.com/2019/05/22/49580-shares-in-anavex-life-sciences-corp-avxl-purchased-by-virtu-financial-llc.html.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which has completed Phase 2a clinical trial for Alzheimer's disease; and preclinical clinical trials to treat Parkinson's disease, Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis.

Featured Story: What are no-load funds?

Institutional Ownership by Quarter for Anavex Life Sciences (NASDAQ:AVXL)

Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply